Proprietary nSMART CAR-T Technology
Chimeric antigen receptor (CAR) T cell therapy stands as a transformative advancement and has achieved unprecedented success in cancer immunotherapy. However, there are many challenges limiting its application in solid tumors and hematological malignancies, including life-threatening CAR-T cell associated toxicities, limited efficacy against solid tumors, inhibition and resistance in B cell malignancies, antigen escape, limited persistence, poor trafficking and tumor infiltration, and the immunosuppressive microenvironment.
Nova Therapeutics has developed its own proprietary nSMART CAR-T technology to address the challenges of traditional CAR-T therapy. Our platform enables the effective improvement of the killing efficacy of CAR-T cells against tumors, alleviation of adverse effects, and reduction of the risk of relapse by the distinguished characteristics of the followings:
Switchable
- Precise control of CAR-T cell activation
- Minimize TLS(tumor lysis syndrome) & CRS(cytokine release syndrome)
- Overcome tumor heterogeneity
- Leveraging target antigen density
- Combating antigen-loss/mutation
Immune-Modulatory
- Activate and engage TILs( tumor-infiltrating lymphocytes) in-situ
- Reduce systemic immune modulator exposure
ARmored
- Improve CAR-T cell fitness and persistence
- Improve immunological memory
- Prevent immune suppression in TME